These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20552899)

  • 1. [Gastrointestinal injuries in patients with breast cancer treated with chemotherapy].
    Koroleva IA; Vel'sher LZ; Kaziulin AN; Kucheriavyĭ IuA; Oganesian TS
    Vopr Onkol; 2010; 56(2):206-9. PubMed ID: 20552899
    [No Abstract]   [Full Text] [Related]  

  • 2. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
    Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
    Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The development of breast cancer therapy in Germany in 2004].
    Haller U; Winter R; Untch M
    Gynakol Geburtshilfliche Rundsch; 2004 Apr; 44(2):61-2. PubMed ID: 15067227
    [No Abstract]   [Full Text] [Related]  

  • 5. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm.
    Bellati F; Napoletano C; Gasparri ML; Panici PB; Nuti M
    J Clin Oncol; 2010 Sep; 28(27):e471-2; author reply e473. PubMed ID: 20585098
    [No Abstract]   [Full Text] [Related]  

  • 7. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B; Yang DQ; Xie F
    Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary systemic chemotherapy for breast conserving surgery].
    Fukutomi T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():507-10. PubMed ID: 17682202
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Taxanes in neojuvant radio-, chemoradio- and chemotherapy for breast cancer].
    Bozhok AA; Semiglazov VF; Kletzel' AE; Arzumanov AS; Mel'nikova OA; Paltuev RM; Ivanova OA; Semiglazov VV
    Vopr Onkol; 2006; 52(1):7-14. PubMed ID: 16715697
    [No Abstract]   [Full Text] [Related]  

  • 14. Taxanes and anthracyclines in early breast cancer: which first?
    Wildiers H; Forceville K; Paridaens R; Joensuu H
    Lancet Oncol; 2010 Mar; 11(3):219-20. PubMed ID: 20202604
    [No Abstract]   [Full Text] [Related]  

  • 15. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
    Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
    Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
    Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
    Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
    J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant chemotherapy of patients with breast carcinoma].
    Jakesz R; Taucher S; Gnant M; Gebhard B; Kandioler D; Rudas M; Djavanmard M; Steger G
    Zentralbl Chir; 1998; 123 Suppl 5():147-50. PubMed ID: 10063601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.